The U.S. Food and Drug Administration (FDA) approved a novel targeted drug to treat acute myelogenous leukemia (AML) in older patients, a segment of the blood cancer population in dire need of improved therapies. In a phase 3 clinical trial, researchers showed that the oral drug, venetoclax (or Venclexta), when given along with azacitidine, could … Read more
Leukemia is a blood cancer that results when stem cells in the bone marrow produce abnormal blood cells.
The U.S. Food and Drug Administration (FDA) has signed off on a new targeted treatment for some patients with acute myeloid leukemia (AML), an often aggressive disease and the most common adult acute leukemia. The FDA approved the drug Idhifa (enasidenib) specifically for the treatment of adult patients with relapsed or refractory AML who have … Read more
After walking 1,000 miles in his bare feet to escape war, and then flying 7,000 more to a new life, it was a few, short steps into a hospital room that helped Panther Ajak Mayen complete his journey. One of the “Lost Boys of Sudan” who escaped a civil war in his homeland 30 years … Read more
By Ronni Gordon When my year of isolation ended after a stem cell transplant at Dana-Farber/Brigham and Women’s Cancer Center in 2003, I looked for a blood cancer support group near my home in western Massachusetts. I found support groups for just about everyone except patients like me with acute myeloid leukemia (AML) and other … Read more
Active in physical pursuits and a world traveler, Harry Beskind, MD, was surprised when he started feeling tired while on a bike ride in 2014. He had just returned home from a river trip to Portugal with his wife, and Beskind, then 82, was having trouble riding up hills on his bike. “I thought I was just … Read more
It looked like a scientific dead end – a clinical trial that found no benefit to a potential drug for a form of leukemia. But, like police detectives working a cold case, Dana-Farber scientists gathered hundreds of tissue samples that had been collected for the study – most of them languishing in laboratory cabinets, destined … Read more